In addition, the use of ACEI/ARB drugs increases the level of ACE2, as well as the wide distribution of ACE2 in pancreas, lung, kidney, heart, and vascular endothelium, which may be an important cause of poor prognosis in patients with COVID-19 and diabetes mellitus. The gene discussed is ACE2; the disease is diabetes mellitus.